Medtronic Makes Two Strategic Acquisitions Exceeding $1 Billion in Early 2026

　　【Pharmaceutical Network Enterprise NewsSince the beginning of 2026, the global medical device sector has seen a continuous rise in mergers and acquisitions, with mega-deals occurring frequently. For instance, Danaher announced the acquisition of patient monitoring company Masimo for approximately $9.9 billion, while Boston Scientific acquired Penumbra, a leader in neurovascular and peripheral interventions, for $14.5 billion. Additionally, top medical device companies such as Smith & Nephew and Johnson & Johnson have also completed acquisition projects. Notably, within just over two months, Medtronic has consecutively announced two acquisitions each exceeding $500 million.
 

Recently, Medtronic announced that it has agreed to acquire Scientia Vascular, headquartered in the United States, for a transaction valued at $5.5 billion, aiming to expand its stroke treatment product line. The transaction is expected to be completed in the first half of fiscal year 2027.
 

Data shows that Scientia Vascular mainly operates guidewires and catheter products for cerebral vascular interventional surgeries. These guidewires and catheters can be seamlessly integrated with Medtronic's existing neurovascular product portfolio. This transaction will enable Medtronic to have a complete product system that supports the entire process of surgeries for hemorrhagic stroke and acute ischemic stroke.
 

This is Medtronic's second bolt-on transaction since 2026. In February, Medtronic announced it would exercise its option to acquire CathWorks, an Israeli cardiovascular AI (artificial intelligence) imaging company, for up to $585 million (approximately 4 billion RMB), further strengthening its cardiovascular product portfolio.
 

It is reported that Medtronic and CathWorks have a long-standing partnership, with Medtronic having invested as early as 2018 and reaching a co-promotion agreement in 2022. Additionally, Medtronic holds the option to acquire CathWorks for up to $585 million before July 2027. This acquisition marks the "natural progression" of their relationship.
 

CathWorks focuses on developing cardiovascular imaging and treatment solutions based on computer vision and artificial intelligence technologies. It is committed to providing objective data for percutaneous coronary intervention (PCI) decision-making and elevating coronary angiography from visual assessment to a decision-making tool based on FFR (fractional flow reserve). Its core product, the FFRangio® system, can utilize routine angiographic images to perform non-invasive coronary physiology assessments through artificial intelligence and advanced computing. This directly addresses the pain points of traditional invasive pressure wire operations being complex and having limited application.
 

Through this transaction, Medtronic not only gained a core technology but also advanced the development of future "intelligent catheterization labs," aiming to guide personalized coronary treatment plans through real-time data.
 

Industry analysis believes that Medtronic's series of transactions at the beginning of 2026 and in recent years are a strategic epitome of its profound transformation from pursuing scale expansion as a "behemoth" to becoming an "industry leader" focused on core sectors, embracing technological integration, and providing solutions. In the future, it will continue to advance in PFA, renal denervation, and surgery.Robot...in fields with high technical barriers and fast market growth, such as neuroscience, actively carry out acquisitions to strengthen differentiated products.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.